ImClone Investigational Site

Dallas, Texas 75390-8852

0 studies enrolling now · 9 studies all time

What they study most

Breast Cancer, Carcinoma, Colorectal Cancer, Colorectal Neoplasms, Metastatic Malignant Melanoma, Metastatic Pancreatic Cancer, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Prostate Cancer

Studies at this site

• A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer — Completed
• Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients — Completed
• A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer — Completed
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
• A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma — Completed
• Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer — Stopped early
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed
• A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer — Completed